Evotec and C4X Discovery Holdings have entered a research collaboration to optimize Orexin-1 selective inhibitors using C4XD’s NMR technology. Evotec will apply its drug discovery platform with C4XD to further develop several series of Orexin-1 selective inhibitors with the goal of developing treatments for addictive disorders.   Activation of the orexin-1 receptor in the brain is associated with stress-related addictive disorders (e.g. alcohol, nicotine, cocaine and opiates), while the ac...